SYBX Stock - Synlogic, Inc.
Unlock GoAI Insights for SYBX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8,000 | $3.37M | $1.18M | $1.75M | $545,000 |
| Gross Profit | $8,000 | $3.37M | $1.18M | $1.75M | $545,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-40,950,000 | $-55,161,000 | $-67,419,000 | $-60,765,000 | $-60,466,000 |
| Net Income | $-23,359,000 | $-57,282,000 | $-66,147,000 | $-60,561,000 | $-59,173,000 |
| Net Margin | -291987.5% | -1699.3% | -5605.7% | -3452.7% | -10857.4% |
| EPS | $-1.92 | $-8.81 | $-13.57 | $-15.76 | $-23.67 |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
SYBXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.11 | $-0.19 | -72.7% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.13 | $-0.04 | +69.2% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.18 | $-0.01 | +94.4% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.51 | $0.16 | +131.4% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.80 | $-2.60 | -225.0% | ✗ MISS |
Q1 2024 | Mar 19, 2024 | $-1.11 | $-1.71 | -54.1% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-2.55 | $-2.57 | -0.8% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-3.90 | $-3.15 | +19.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-3.75 | $-3.45 | +8.0% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-3.90 | $-3.60 | +7.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-3.45 | $-3.75 | -8.7% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-3.45 | $-3.30 | +4.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-3.45 | $-3.30 | +4.3% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-4.05 | $-3.15 | +22.2% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-4.35 | $-4.35 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-4.35 | $-4.20 | +3.4% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-5.85 | $-5.40 | +7.7% | ✓ BEAT |
Q1 2021 | Mar 25, 2021 | $-6.00 | $-5.85 | +2.5% | ✓ BEAT |
Frequently Asked Questions about SYBX
What is SYBX's current stock price?
What is the analyst price target for SYBX?
What sector is Synlogic, Inc. in?
What is SYBX's market cap?
Does SYBX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SYBX for comparison